KCNH1 and cancer: Currently, different pharmacological strategies (small molecules, antibodies, siRNA) to target Kv10.1 have shown positive results (Menéndez et al., 2012; Bernal-Ramos et al., 2017; Valdés-Abadía et al., 2019; Hartung et al., 2020; Toplak et al., 2021; 2022), decreasing some properties of cancer cells.